Travere Therapeutics (TVTX) Amortizatization of Intangibles (2011 - 2023)
Travere Therapeutics' (TVTX) quarterly Amortizatization of Intangibles came in at $2.3 million in Q4 2023, up 122.39% YoY from $1.0 million in Q4 2022, and up 22.84% on a QoQ basis from $1.9 million in Q3 2023.
Analysis
Travere Therapeutics (TVTX) Amortizatization of Intangibles (2011 - 2023) Analysis & Trends
Travere Therapeutics (TVTX) has 11 years of Amortizatization of Intangibles data on file, last reported at $2.3 million in Q4 2023.
- Quarterly Amortizatization of Intangibles rose 122.39% year-over-year to $2.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $5.7 million (up 717.43% YoY) and the FY2025 annual result came in at $4.4 million, down 2.18% from the prior year.
- Amortizatization of Intangibles rose to $2.3 million in Q4 2023, from $1.9 million in the prior quarter.
- In the past five years, Amortizatization of Intangibles ranged from a high of $2.3 million in Q4 2023 to a low of -$697000.0 in Q4 2021.
- A 5-year average of $161333.3 and a median of -$155500.0 in 2020 frame the typical range for Amortizatization of Intangibles.
- Annual changes were most pronounced in 2019 — Amortizatization of Intangibles soared 295.1% — and 2020, when it sank 2022.22%.
- Tracing TVTX's Amortizatization of Intangibles over 5 years: stood at $9000.0 in 2019, then slumped by 2022.22% to -$173000.0 in 2020, then plunged by 302.89% to -$697000.0 in 2021, then soared by 246.77% to $1.0 million in 2022, then jumped by 122.39% to $2.3 million in 2023.
- The last three Amortizatization of Intangibles figures came in at $2.3 million (Q4 2023), $1.9 million (Q3 2023), and $1.0 million (Q4 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Travere Therapeutics | 6.11 Bn | 6.11 Bn | 162.52 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | 2.28 Mn |
| Sep 30, 2023 | 1.85 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 572,000.00 |
| Jun 30, 2022 | -222,000.00 |
| Mar 31, 2022 | -673,000.00 |
| Dec 31, 2021 | -697,000.00 |
| Sep 30, 2021 | -651,000.00 |
| Jun 30, 2021 | -483,000.00 |
| Mar 31, 2021 | -177,000.00 |
| Dec 31, 2020 | -173,000.00 |
| Sep 30, 2020 | -193,000.00 |
| Jun 30, 2020 | -199,000.00 |
| Mar 31, 2020 | -138,000.00 |
| Dec 31, 2019 | 9,000.00 |
| Sep 30, 2019 | 199,000.00 |
| Jun 30, 2019 | 237,000.00 |
| Mar 31, 2019 | 343,000.00 |
| Dec 31, 2018 | 1.21 Mn |
| Sep 30, 2018 | -102,000.00 |